Fennec Pharmaceuticals has resubmitted their New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARK™, a unique sodium thiosulfate formulation. PEDMARK is designed to prevent ototoxicity caused by cisplatin chemotherapy in patients under 18 years of age diagnosed with non-metastatic, localized solid tumors. If approved, PEDMARK will be the first drug therapy for the prevention of cisplatin-induced hearing loss in children. Rosty Raykov, CEO of Fennec Pharmaceuticals, Inc., stated, “We are pleased to have resubmitted the NDA for PEDMARK™ and look forward to working with the FDA through the review process.”
Read more here.